Sentence: Forthcoming data from phase 3 placebo-controlled trials of everolimus , one focused on monotherapy for pancreatic NET and the other on combination use with octreotide LAR for patients with advanced NET and a history of carcinoid syndrome , will provide insight into its future place in NET therapy .
Drug combination annotation:
[{'class': 'COMB', 'spans': ['everolimus', 'octreotide'], 'is_context_needed': True}]